Teva Pharmaceutical Industries Limited Stock TEL AVIV STOCK EXCHANGE
Stocks
IL0006290147
Pharmaceuticals
OTC Markets Traded| Market Cap | 46.06B 14,082B 41.05B 38.27B 34.83B 65.67B 4,436B 66.08B 462B 180B 2,262B 173B 169B 7,271B | P/E 2026 * |
42.6x | P/E 2027 * | 18.6x |
|---|---|---|---|---|---|
| Enterprise Value | 57.43B 17,557B 51.18B 47.71B 43.43B 81.87B 5,531B 82.38B 576B 224B 2,820B 216B 211B 9,066B | EV / Sales 2026 * |
3.45x | EV / Sales 2027 * | 3.17x |
| Free-Float |
91.17% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Teva Pharmaceutical Industries Limited
| 1 day | -3.96% |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 57 | 01/01/2023 |
Eli Kalif
DFI | Director of Finance/CFO | 53 | 22/12/2019 |
Matthew Shields
COO | Chief Operating Officer | 52 | 03/06/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Amir Elstein
BRD | Director/Board Member | 69 | 01/01/2009 |
Sol Barer
CHM | Chairman | 78 | 06/02/2017 |
Rosemary Crane
BRD | Director/Board Member | 65 | 01/09/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.96% | -3.32% | - | - | 46.06B | |
| +0.02% | -3.41% | +36.11% | +115.09% | 1,019B | |
| -1.21% | -6.74% | +34.08% | +62.64% | 617B | |
| +1.12% | +0.54% | +13.62% | +79.94% | 464B | |
| -3.30% | -6.21% | +56.45% | +36.58% | 356B | |
| +0.93% | -3.16% | +21.65% | +43.02% | 333B | |
| +0.12% | -2.77% | +10.70% | +32.97% | 267B | |
| -0.89% | -6.28% | -7.00% | +8.01% | 244B | |
| -0.01% | -2.81% | +35.28% | +51.82% | 218B | |
| -0.08% | -4.17% | +28.34% | +93.51% | 179B | |
| Average | -0.65% | -3.54% | +25.47% | +58.17% | 410.8B | |
| Weighted average by Cap. | -0.09% | -3.54% | +28.50% | +70.11% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 16.65B 5,091B 14.84B 13.84B 12.59B 23.74B 1,604B 23.89B 167B 64.95B 818B 62.52B 61.17B 2,629B | 17.26B 5,277B 15.38B 14.34B 13.05B 24.61B 1,662B 24.76B 173B 67.31B 848B 64.8B 63.39B 2,725B |
| Net income | 1.33B 407B 1.19B 1.11B 1.01B 1.9B 128B 1.91B 13.36B 5.19B 65.38B 5B 4.89B 210B | 2.55B 779B 2.27B 2.12B 1.93B 3.63B 245B 3.65B 25.56B 9.93B 125B 9.56B 9.36B 402B |
| Net Debt | 11.37B 3,475B 10.13B 9.44B 8.6B 16.2B 1,095B 16.3B 114B 44.33B 558B 42.67B 41.75B 1,794B | 8.71B 2,661B 7.76B 7.23B 6.58B 12.41B 838B 12.49B 87.33B 33.95B 428B 32.68B 31.97B 1,374B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
